Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026

Equillium, Inc.

2026-Q1 EPS reported -$0.06 vs consensus -$0.04 ▼ miss (-34.5%)

Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.
Cash and equivalents $61.3M as of March 31, 2026; funded into 2029; includes $35M March private placement.
Phase 1 proof-of-mechanism study of EQ504 (AhR modulator) on track for mid-2026, data ~6 months later.
Appointed Snehal Naik, Ph.D., as Chief Development Officer; she brings >15 years immunology experience.
Evaluating further advancement of EQ302 (IL-15/IL-21 inhibitor) for GI indications.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Equillium, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $5.3 million, or $(0.06) per basic and diluted share, EPS $(0.06) per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $5.3 million, or $(0.06) per basic and diluted share
EPS: $(0.06) per basic and diluted share
Result: reported results

Exact text from the filing

On May 13, 2026, Equillium, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.